News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diazyme Laboratories Introduces New Test for the Early Detection of Kidney Disease


2/26/2008 9:40:58 AM

POWAY, CA--(Marketwire - February 25, 2008) - Diazyme Laboratories announced today that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its Cystatin C Assay Kit for the quantitative determination of Cystatin C in serum and plasma samples. Cystatin C is emerging as a biomarker superior to standard tests of kidney function in the early detection of chronic kidney disease. There is a growing body of evidence that indicates that some of the negative outcomes of chronic kidney disease can be averted with early diagnosis and treatment.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES